| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
China National Accord Medicines Corporation Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥34.00 |
| 52 Week High | CN¥52.55 |
| 52 Week Low | CN¥26.06 |
| Beta | 0.32 |
| 1 Month Change | 8.11% |
| 3 Month Change | 21.04% |
| 1 Year Change | -18.47% |
| 3 Year Change | 1.33% |
| 5 Year Change | -7.10% |
| Change since IPO | -38.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| 28 | CN Healthcare | CN Market | |
|---|---|---|---|
| 7D | 10.9% | -5.0% | -4.9% |
| 1Y | -18.5% | -36.7% | -21.1% |
Return vs Industry: 000028 exceeded the CN Healthcare industry which returned -36.7% over the past year.
Return vs Market: 000028 exceeded the CN Market which returned -21.1% over the past year.
Price Volatility
| 28 volatility | |
|---|---|
| 28 Average Weekly Movement | 5.9% |
| Healthcare Industry Average Movement | 6.9% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.4% |
| 10% least volatile stocks in CN Market | 5.4% |
Stable Share Price: 000028 has not had significant price volatility in the past 3 months.
Volatility Over Time: 000028's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 39,449 | Zhaoxiong Lin | www.szaccord.com.cn |
China National Accord Medicines Corporation Ltd. engages in the retail and distribution of pharmaceutical products in China and internationally. it offers drugs, medical equipment, cargo transportation, warehousing, loading and unloading, glass instruments, cosmetics, sales of daily necessities, other business services, other professional consulting, and self-management services; agent services; import and export of various commodities and technologies; and house leasing services.
China National Accord Medicines Corporation Ltd. Fundamentals Summary
| 28 fundamental statistics | |
|---|---|
| Market cap | CN¥17.46b |
| Earnings (TTM) | CN¥1.60b |
| Revenue (TTM) | CN¥75.48b |
11.8x
P/E Ratio0.3x
P/S RatioIs 28 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 28 income statement (TTM) | |
|---|---|
| Revenue | CN¥75.48b |
| Cost of Revenue | CN¥66.47b |
| Gross Profit | CN¥9.01b |
| Other Expenses | CN¥7.41b |
| Earnings | CN¥1.60b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 26, 2024
| Earnings per share (EPS) | 2.87 |
| Gross Margin | 11.93% |
| Net Profit Margin | 2.12% |
| Debt/Equity Ratio | 13.9% |
How did 28 perform over the long term?
See historical performance and comparison